Summary
It has been established that successful pancreas transplantation in Type 1 (insulin-dependent) diabetic patients results in normal but exaggerated phasic glucose-induced insulin secretion, normal intravenous glucose disappearance rates, improved glucose recovery from insulin-induced hypoglycaemia, improved glucagon secretion during insulin-induced hypoglycaemia, but no alterations in pancreatic polypeptide responses to hypoglycaemia. However, previous reports have not segregated the data in terms of the length of time following successful transplantation and very little prospective data collected over time in individual patients has been published. This article reports that in general there are no significant differences in the level of improvement when comparing responses as early as three months post-operatively up to as long as two years post-operatively when examining the data cross-sectionally in patients who have successfully maintained their allografts. Moreover, this remarkable constancy in pancreatic islet function is also seen in a smaller group of patients who have been examined prospectively at various intervals post-operatively. It is concluded that successful pancreas transplantation results in remarkable improvements in Alpha and Beta cell but not PP cell function that are maintained for at least one to two years.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Bosi E, Piatti PM, Secchi A, Monti LD, Traeger J, Dubernard JM, Pozza G (1988) Response of glucagon and insulin secretion to insulin-induced hypoglycemia in type I diabetic recipients after pancreatic transplantation. Diab Nutr Metab 1:21–27
Diem P, Abid M, Redmon JB, Sutherland DER, Robertson RP (1990) Systemic venous drainage of pancreas allografts as independent cause of hyperinsulinemia in type I diabetic recipients. Diabetes 39:534–540
Diem P, Redmon JB, Abid M, Moran A, Sutherland DER, Halter JB, Robertson RP (1990) Glucagon, catecholamine and pancreatic polypeptide secretion in type I diabetic recipients of pancreas allografts. J Clin Invest 86:2008–2013
Land W, Landgraf R, Illner W-D, Abendroth D, Kampik A, Jensen U, Lenhart FP, Burg D, Hillebrand G, Castro LA, Landgraf-Lewis MMC, Frey L, Gokel M, Schleibner St, Nusser J, Ulbig M (1987) Clinical pancreatic transplantation using the prolamine duct occlusion technique: the Munich experience. Transplant Proc 19 (Suppl 4):75–83
Osei K, Henry ML, O'Dorisio TM, Tesi RJ, Sommer BG, Ferguson RM (1990) Physiological and pharmacological stimulation of pancreatic islet hormone secretion in type I diabetic pancreas allograft recipients. Diabetes 39:1235–1242
Östman J, Bolinder J, Gunnarsson R, Brattstrom C, Tyden G, Wahren J, Groth C-G (1989) Metabolic effects of pancreas transplantation: effects of pancreas transplantation on metabolic and hormonal profiles in IDDM patients. Diabetes 38 (Suppl 1):88–93
Secchi A, Pontiroli AE, Bosi E, Piatti PM, Touraine JL, Monti LD, Gelet A, Traeger J, Dubernard JM, Pozza G (1987) Effects of arginine and arginine plus somatostatin infusion on insulin release in diabetic patients submitted to pancreas allotransplantation. Diabete Metab 13:422–425
Sutherland DER, Dunn DL, Goetz FC, Kennedy W, Ramsay RC, Steffes MW, Mauer SM, Gruessner R, Moudry-Munns KC, Morel P, Viste A, Robertson RP, Najarian JS (1989) A 10-year experience with 290 pancreas transplants at a single institution. Ann Surg 210:274–288
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Robertson, R.P., Diem, P. & Sutherland, D.E.R. Time-related, cross-sectional and prospective follow-up of pancreatic endocrine function after pancreas allograft transplantation in Type 1 (insulin-dependent) diabetic patients. Diabetologia 34 (Suppl 1), S57–S60 (1991). https://doi.org/10.1007/BF00587621
Issue Date:
DOI: https://doi.org/10.1007/BF00587621